Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00553267




Registration number
NCT00553267
Ethics application status
Date submitted
8/10/2007
Date registered
4/11/2007
Date last updated
13/02/2014

Titles & IDs
Public title
Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension
Scientific title
An Eight-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 40mg + Amlodipine 10mg Versus Telmisartan 80mg + Amlodipine 10mg Versus Amlodipine 10mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 10mg Monotherapy
Secondary ID [1] 0 0
EUDRACT 2007-002421-68
Secondary ID [2] 0 0
1235.6
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypertension 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Trough Seated Diastolic Blood Pressure
Timepoint [1] 0 0
Baseline and end of study (8 weeks or last value on treatment)
Secondary outcome [1] 0 0
Change From Baseline in Trough Seated Systolic Blood Pressure
Timepoint [1] 0 0
Baseline and end of study (8 weeks or last value on treatment)
Secondary outcome [2] 0 0
Trough Seated Diastolic Blood Pressure Control (Defined as < 90mmHg)
Timepoint [2] 0 0
End of study (8 weeks or last value on treatment)
Secondary outcome [3] 0 0
Trough Seated Diastolic Blood Pressure <80 mmHg
Timepoint [3] 0 0
End of study (8 weeks or last value on treatment)
Secondary outcome [4] 0 0
Trough Seated DBP Response
Timepoint [4] 0 0
End of study (8 weeks or last value on treatment)
Secondary outcome [5] 0 0
Trough Seated SBP Control
Timepoint [5] 0 0
End of study (8 weeks or last value on treatment)
Secondary outcome [6] 0 0
Trough Seated SBP Response
Timepoint [6] 0 0
End of study (8 weeks or last value on treatment)
Secondary outcome [7] 0 0
Trough Seated BP Normality Classes
Timepoint [7] 0 0
End of study (8 weeks or last value on treatment)
Secondary outcome [8] 0 0
Oedema Incidence Rate
Timepoint [8] 0 0
During randomised treatment period
Secondary outcome [9] 0 0
Peripheral Oedema Incidence Rate
Timepoint [9] 0 0
During randomised treatment period

Eligibility
Key inclusion criteria
* diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent (inadequate control defined as seated diastolic blood pressure (DBP) >= 95 mmHg if on existing antihypertensive treatment or seated DBP >= 100 mmHg if treatment-naïve).
* failure to respond to six weeks treatment with amlodipine 10mg. (Failure to respond defined as seated DBP >= 90 mmHg.)
* able to stop any current antihypertensive therapy without unacceptable risk to the patient.
* willing and able to provide written informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).
* known or suspected secondary hypertension.
* mean seated systolic blood pressure (SBP) >=200 mmHg and/or mean seated DBP >= 120 mmHg during run-in treatment or mean seated SBP >= 180 mmHg and/or mean seated DBP >= 120 mmHg at the randomisation visit or at any time during randomised treatment.
* any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.
* clinically relevant hyperkalaemia.
* uncorrected volume or sodium depletion.
* primary aldosteronism.
* hereditary fructose or lactose intolerance.
* symptomatic congestive heart failure.
* patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or ARBs.
* history of drug or alcohol dependency within the six months prior to signing consent.
* concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing consent.
* hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.
* known allergic hypersensitivity to any component of the formulations under investigation. (Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine CCBs.)
* non-compliance with study medication (defined as less than 80% or more than 120%) during the open-label run-in treatment period.
* current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigator¿s decision) by the start of the run-in period.
* chronic administration of any medication known to affect blood pressure, other than the trial medication.
* any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.

Study design
Purpose of the study
Treatment
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/11/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
947
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA
Recruitment hospital [1] 0 0
1235.6.61003 Boehringer Ingelheim Investigational Site - Gosford
Recruitment hospital [2] 0 0
1235.6.61004 Boehringer Ingelheim Investigational Site - Liverpool
Recruitment hospital [3] 0 0
1235.6.61002 Boehringer Ingelheim Investigational Site - Kippa-Ring
Recruitment hospital [4] 0 0
1235.6.61001 Boehringer Ingelheim Investigational Site - Milton
Recruitment hospital [5] 0 0
1235.6.61005 Boehringer Ingelheim Investigational Site - Elizabeth Vale
Recruitment postcode(s) [1] 0 0
- Gosford
Recruitment postcode(s) [2] 0 0
- Liverpool
Recruitment postcode(s) [3] 0 0
- Kippa-Ring
Recruitment postcode(s) [4] 0 0
- Milton
Recruitment postcode(s) [5] 0 0
- Elizabeth Vale
Recruitment outside Australia
Country [1] 0 0
Austria
State/province [1] 0 0
Eggenburg
Country [2] 0 0
Austria
State/province [2] 0 0
Hainburg a.d. Donau
Country [3] 0 0
Austria
State/province [3] 0 0
Hartberg
Country [4] 0 0
Austria
State/province [4] 0 0
Wien
Country [5] 0 0
Bulgaria
State/province [5] 0 0
Bourgas
Country [6] 0 0
Bulgaria
State/province [6] 0 0
Sofia
Country [7] 0 0
Bulgaria
State/province [7] 0 0
Varna
Country [8] 0 0
Czech Republic
State/province [8] 0 0
Benatky nad Jizerou
Country [9] 0 0
Czech Republic
State/province [9] 0 0
Brno
Country [10] 0 0
Czech Republic
State/province [10] 0 0
Plzen
Country [11] 0 0
Czech Republic
State/province [11] 0 0
Praha 5
Country [12] 0 0
Czech Republic
State/province [12] 0 0
Pribram
Country [13] 0 0
Czech Republic
State/province [13] 0 0
Slany
Country [14] 0 0
Czech Republic
State/province [14] 0 0
Strakonice
Country [15] 0 0
Ireland
State/province [15] 0 0
Birr
Country [16] 0 0
Ireland
State/province [16] 0 0
Carrigtwohill
Country [17] 0 0
Ireland
State/province [17] 0 0
Enniscorthy
Country [18] 0 0
Ireland
State/province [18] 0 0
Gorey
Country [19] 0 0
Ireland
State/province [19] 0 0
Mallow
Country [20] 0 0
Ireland
State/province [20] 0 0
New Ross
Country [21] 0 0
Italy
State/province [21] 0 0
Broni (pv)
Country [22] 0 0
Italy
State/province [22] 0 0
Coppito (AQ)
Country [23] 0 0
Italy
State/province [23] 0 0
Ferrara
Country [24] 0 0
New Zealand
State/province [24] 0 0
Dunedin
Country [25] 0 0
New Zealand
State/province [25] 0 0
Otahuhu, Auckland
Country [26] 0 0
New Zealand
State/province [26] 0 0
Tauranga
Country [27] 0 0
Russian Federation
State/province [27] 0 0
Moscow
Country [28] 0 0
Russian Federation
State/province [28] 0 0
St. Petersburg
Country [29] 0 0
Slovakia
State/province [29] 0 0
Dolny Kubin
Country [30] 0 0
Slovakia
State/province [30] 0 0
Kralovsky Chmlec
Country [31] 0 0
Slovakia
State/province [31] 0 0
Liptovsky Mikulas
Country [32] 0 0
Slovakia
State/province [32] 0 0
Povazska Bystrica
Country [33] 0 0
Slovakia
State/province [33] 0 0
Presov
Country [34] 0 0
Slovakia
State/province [34] 0 0
Trencin
Country [35] 0 0
Slovakia
State/province [35] 0 0
Vrable
Country [36] 0 0
Spain
State/province [36] 0 0
Badalona
Country [37] 0 0
Spain
State/province [37] 0 0
Barcelona
Country [38] 0 0
Spain
State/province [38] 0 0
Jerez de la Frontera (Cádiz)
Country [39] 0 0
Spain
State/province [39] 0 0
L'Hospitalet de Llobregat (Barcelona)
Country [40] 0 0
Spain
State/province [40] 0 0
Madrid
Country [41] 0 0
Spain
State/province [41] 0 0
Santa Coloma de Gramanet
Country [42] 0 0
Switzerland
State/province [42] 0 0
Gordola
Country [43] 0 0
Turkey
State/province [43] 0 0
Erzurum
Country [44] 0 0
Turkey
State/province [44] 0 0
Istanbul
Country [45] 0 0
Turkey
State/province [45] 0 0
Izmir
Country [46] 0 0
Ukraine
State/province [46] 0 0
Dnepropetrovsk
Country [47] 0 0
Ukraine
State/province [47] 0 0
Kharkov
Country [48] 0 0
Ukraine
State/province [48] 0 0
Kiev
Country [49] 0 0
Ukraine
State/province [49] 0 0
Lvov
Country [50] 0 0
Ukraine
State/province [50] 0 0
Odessa
Country [51] 0 0
Ukraine
State/province [51] 0 0
Zaporozhye
Country [52] 0 0
United Kingdom
State/province [52] 0 0
Bexhill
Country [53] 0 0
United Kingdom
State/province [53] 0 0
Blackpool
Country [54] 0 0
United Kingdom
State/province [54] 0 0
Burbage, Hinkley
Country [55] 0 0
United Kingdom
State/province [55] 0 0
Chestfield, Whitstable
Country [56] 0 0
United Kingdom
State/province [56] 0 0
Chorley
Country [57] 0 0
United Kingdom
State/province [57] 0 0
Edgbaston, Birmingham
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Ely
Country [59] 0 0
United Kingdom
State/province [59] 0 0
Fowey
Country [60] 0 0
United Kingdom
State/province [60] 0 0
Glasgow
Country [61] 0 0
United Kingdom
State/province [61] 0 0
Penzance
Country [62] 0 0
United Kingdom
State/province [62] 0 0
Plymouth
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Reading
Country [64] 0 0
United Kingdom
State/province [64] 0 0
Saltash
Country [65] 0 0
United Kingdom
State/province [65] 0 0
St Stephen, St Austell
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Whitstable

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Boehringer Ingelheim
Address 0 0
Boehringer Ingelheim
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00553267